Topics:
Gynecologic Cancers • Endometrial Cancer • Medical Oncology • Journal Club ft. NEJM publications
Is there a difference in survival or disease response between patients with recurrence free interval ≥1 vs <1 year from platinum-based cytotoxic therapy who are treated with pembrolizumab + lenvatinib?
In the KEYNOTE-775 study, what was the proportion of patients who had a recurrence free interval ≥1 year from platinum-based cytotoxic chemotherapy?
Answer from: at Academic Institution
As presented by Dr. Columbo at ESMO 2021, the OS favored len/pem with an HR of 0.65 (0.52-0.81) in pMMR pts with a PFI <12 mo while the HR was 0.75 (0.36-1.58) in those with a PFI >12 mo.
Sign in or Register to read more